Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.

MLA

Low, Ee Vien, et al. “Nirmatrelvir/Ritonavir Treatment and the Risk of Post-COVID Condition over 180 Days in Malaysia.” BMC Infectious Diseases, vol. 24, no. 1, Aug. 2024, p. 780. EBSCOhost, https://doi.org/10.1186/s12879-024-09679-1.

APA

Low, E. V., Pathmanathan, M. D., Ten, Y. Y., Chidambaram, S. K., Kim, W. R., Lee, W. J., Teh, Z. W., Appannan, M. R., Ismail, M., Samad, A. A., & Peariasamy, K. M. (2024). Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia. BMC Infectious Diseases, 24(1), 780. https://doi.org/10.1186/s12879-024-09679-1

Chicago

Low, Ee Vien, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, et al. 2024. “Nirmatrelvir/Ritonavir Treatment and the Risk of Post-COVID Condition over 180 Days in Malaysia.” BMC Infectious Diseases 24 (1): 780. doi:10.1186/s12879-024-09679-1.